$AKAM

AKAMAI TECHNOLOGIES INC

AlphAI earnings readSecond quarter 2026 · AUG 6 · NEXT NOV 5Second quarter revenue of $1.1 billion, up 5% year-over-year and when adjusted for foreign exchangeVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
5
2

No SEC Form 4 filings for $AKAM in the last 30 days.

See all $AKAM insider activity →

AI agents can run code they write in a separate space. Akamai's tools are in beta.

Akamai (AKAM) introduced Akamai Inference and Akamai Agent Sandbox, extending its cloud platform to manage and secure AI applications. These tools allow enterprises to build, run, and secure AI models and agents, with features like managed model serving and isolated execution. The products are in beta, with Akamai also expanding its GPU fleet to include NVIDIA Blackwell Ultra clusters.

AKAM sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 9 news stories mentioning AKAM (AKAMAI TECHNOLOGIES INC). Coverage has been balanced: 2 bullish, 5 neutral, and 2 bearish.

Recent AKAM coverage spans financial news, technology and market movers.

What's driving AKAM

AlphAI scores every news story that mentions AKAM with an AI model for sentiment and relevance, and aggregates insider trades from AKAMAI TECHNOLOGIES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AKAM

Score

AI agents can run code they write in a separate space. Akamai's tools are in beta.

Akamai (AKAM) introduced Akamai Inference and Akamai Agent Sandbox, extending its cloud platform to manage and secure AI applications. These tools allow enterprises to build, run, and secure AI models and agents, with features like managed model serving and isolated execution. The products are in beta, with Akamai also expanding its GPU fleet to include NVIDIA Blackwell Ultra clusters.

Analyst recommendations: Block, Halliburton, Qiagen, Tesla

Analysts updated ratings and price targets for several companies. Block (SQ) was upgraded to outperform with a target raised to $101. Halliburton (HAL) was upgraded to buy with a target increased to $40. Tesla (TSLA) was upgraded to hold with a target raised to $400. Other companies mentioned include Qiagen (QGEN), CoreWeave (CWV), and Meta (META).

Analyst recommendations: Cirrus Logic, Fortinet, Ge Aerospace, Moderna, Nebius

Analysts updated ratings and price targets for several companies. Barclays downgraded Cirrus Logic (CRUS) to underweight, reducing its target to $95. UBS upgraded Clean Harbors (CLH) to buy, raising its target to $375. Fortinet (FTNT) was downgraded to sell by Arete Research, which increased its target to $117. GE Aerospace (GE) was downgraded to neutral by President Capital Management, cutting its target to $330.

What Does GoDaddy Offer That Akamai Does Not?

Akamai (AKAM) trimmed its 2026 revenue forecast to $4.488B but expects growth to accelerate in 2027, backed by a $11.6B cloud services commitment. GoDaddy (GDDY) maintained its 2026 revenue guidance at $5.215B-$5.255B and reaffirmed its free cash flow target of $1.8B. Akamai is investing heavily in AI, while GoDaddy focuses on share buybacks.

$CRWVMed

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Akamai Technolgies, Apple, Blackrock, Ford Motor, Healthcare Realty Trust, Noble, Sunoco LP, Venture Global, Western Midstream Partners, Zoetis, and More

Wall Street analysts released research calls on various companies. Upgrades include Akamai (AKAM) to Strong Buy, BlackRock (BLK) to Buy, and Venture Global (VG) to Overweight. Downgrades include Apple (AAPL) to Hold, Elanco (ELAN) to Hold, and Zoetis (ZTS) to Hold. Initiations include Ford (F) with Overweight and Sunoco (SUN) with Overweight. Markets were mixed, with Nasdaq futures lower and Treasury yields higher.

$HALLow

Premarket movers: RTX rises, GE slips following quarterly results

U.S. stock index futures were mixed on Tuesday, with tech stocks under pressure. Halliburton (HAL) rose 3.4% after beating earnings expectations. Rapport Therapeutics (RPTX) surged 31.1% on positive Phase 2 trial results. NuScale Power (SMR) fell 6.5% after a downgrade. Akamai (AKAM) gained 2.2% following an upgrade. General Motors (GM) dropped 6.3% after disappointing investors with its outlook. Alvotech (ALVO) rose 7% after FDA approval. 3M (MMM) gained over 1% on Amazon partnership expansion.

Related tickers